Replies to post #115625 on Biotech Values

[mcbio]

To lift the partial FDA clinical hold on IDX184, the FDA will need to see no safety signal in the 28-day data for the first 30 patients to enroll in the phase-2b trial in treatment-naïve genotype-1 patients slated to begin in 2H11. In other words, it will likely be 2012 before the partial clinical hold can be lifted. (Source: Today’s CC)

I doubt I'll even bother to listen to anymore IDIX CCs in the future as it's become pretty clear to me that their prospects are fairly bleak now. I can't imagine any scenario in which I'd ever seriously consider the stock again, regardless of how cheap it gets, just because I think they're in such bad shape now fundamentally. I don't understand how the stock is still holding up fairly well. (I say this and of course they'll probably get acquired soon. LOL)